SCHEMBL480702

SCHEMBL480702

CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](CO)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 8/20 0.63
PRKCE Q02156 2/20 0.46
PRKCQ Q04759 2/20 0.46
PRKCD Q05655 2/20 0.46
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9452155 1.00 PRKCA (0.63) PRKCAPRKCEPRKCQPRKCDBLM
SCHEMBL11896012 1.00 PRKCA (0.63) PRKCAPRKCEPRKCQPRKCDBLM
SCHEMBL30557897 0.91 PRKCA (0.47) PRKCAPRKCEPRKCQPRKCDBLM
SCHEMBL21686371 0.90 PRKCA (0.50) PRKCAPRKCEPRKCQPRKCDBLM
SCHEMBL234142 0.82 ENPP2 (0.51) PRKCA
SCHEMBL23706432 0.82 LMNA (0.46) PRKCABLM
SCHEMBL1521671 0.81 PRKCA (0.42) PRKCABLM
SCHEMBL26236288 0.81 SELP (0.49) PRKCA
SCHEMBL14415223 0.81 PRKCA (0.74) PRKCAPRKCEPRKCQPRKCD
SCHEMBL3574597 0.81 BLM (0.41) PRKCABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098635-A1 NEW CATIONIC LIPID WITH NITROGEN-CONTAINING HETEROCYCLIC HEAD GROUP AND USE THEREOF 厦门赛诺邦格生物科技股份有限公司 2026-05-15 WO claimed
CN-118697900-A Method for preparing lipid nanoparticles 摩登纳特斯有限公司 2024-09-27 CN claimed
WO-2024067816-A1 PEGYLATED LIPID CONTAINING LYSINE CORE 厦门赛诺邦格生物科技股份有限公司 2024-04-04 WO claimed
WO-2024051825-A1 CARBON NUCLEUS CATIONIC LIPID 厦门赛诺邦格生物科技股份有限公司 2024-03-14 WO claimed
WO-2023232148-A1 AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS 厦门赛诺邦格生物科技股份有限公司 2023-12-07 WO claimed
WO-2023232147-A1 AMINO ACID CATIONIC LIPID 厦门赛诺邦格生物科技股份有限公司 2023-12-07 WO claimed
WO-2023198083-A1 NONLINEAR PEGYLATED LIPID CONTAINING TERTIARY AMINE AND APPLICATION THEREOF 厦门赛诺邦格生物科技股份有限公司 2023-10-19 WO claimed
WO-2023198085-A1 NITROGEN-BRANCHED NONLINEAR PEGYLATED LIPID CONTAINING TERTIARY AMINE AND USE THEREOF 厦门赛诺邦格生物科技股份有限公司 2023-10-19 WO claimed
WO-2023198082-A1 NON-LINEAR PEGYLATED LIPID AND APPLICATION THEREOF 厦门赛诺邦格生物科技股份有限公司 2023-10-19 WO claimed
CN-115916163-A Novel lipids and nanoparticle compositions thereof 世代生物公司 2023-04-04 CN claimed
WO-2026103877-A1 LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION 中生复诺健生物科技(上海)有限公司 2026-05-21 WO disclosed
WO-2026098601-A1 LIPID NANOPARTICLE FOR DELIVERING LOAD 北京剂泰生命科技有限公司 2026-05-15 WO disclosed
EP-3682023-B1 TUNING AND CALIBRATION FEATURES OF A SEQUENCE-DETECTION SYSTEM ILLUMINA INC (US) 2026-01-28 EP disclosed
EP-3682020-B1 SEQUENCE-DETECTION SYSTEM ILLUMINA INC (US) 2025-09-03 EP disclosed
US-20250224411-A1 MOLECULAR HOPPER OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2025-07-10 US disclosed
US-11352647-B2 Crispr enzymes and systems THE BROAD INSTITUTE, INC. (US) 2022-06-07 US disclosed
CN-111225744-B Protein nanopores removal and reinsertion into membranes using osmotic imbalance 豪夫迈·罗氏有限公司 2022-05-03 CN disclosed
CN-216337555-U Pore array layer structure, chip device and nanopore sequencing device 成都齐碳科技有限公司 2022-04-19 CN disclosed
EP-2410990-A1 COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING Marval Biosciences, Inc. (US) 2012-02-01 EP disclosed
WO-2010107990-A1 COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING MARVAL BIOSCIENCES, INC. (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352647-B2 Crispr enzymes and systems CPSF1, CPN1, CPSF6 PRKCA 2526/4885PRKCE 2388/4885PRKCQ 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.